White Matter Tracts Differ for Infants With Fragile X Syndrome

Share this content:
White Matter Tracts Differ for Infants With Fragile X Syndrome
White Matter Tracts Differ for Infants With Fragile X Syndrome

MONDAY, April 9, 2018 (HealthDay News) -- There are significant differences in the development of 12 fiber tracts between infants with fragile X syndrome (FXS) and controls, according to a study published online April 4 in JAMA Psychiatry.

Meghan R. Swanson, Ph.D., from the University of North Carolina at Chapel Hill, and colleagues characterized development of white matter at age 6, 12, and 24 months in infants with FXS and typically developing controls. Longitudinal behavioral and brain imaging data were obtained from 27 infants with FXS and 73 typically developing controls with no first- or second-degree relatives with intellectual or psychiatric disorders.

The researchers identified significant differences in the development of 12 of 19 fiber tracts between the infants with FXS and controls, with lower fractional anisotropy in bilateral subcortical-frontal, occipital-temporal, temporal-frontal, and cerebellar-thalamic pathways and in four of six corpus callosum subdivisions. Significant main effects were seen between groups for all 12 of these pathways but not for the interaction of age × group; this indicated that in the FXS group, lower fractional anisotropy was stable from age 6 months. In the FXS group, there was a correlation for lower fractional anisotropy values in the uncinate fasciculi with lower nonverbal development quotient.

"The results substantiate in human infants the essential role of fragile X gene expression in the early development of white matter," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Low-Dose Hyaluronidase Can Remove Hyaluronic Acid Fillers

Low-Dose Hyaluronidase Can Remove Hyaluronic Acid Fillers

Greater resolution of nodules with hyaluronidase versus saline; more rapid resolution with higher doses

Improvement in Race-Based Disparities in Years of Life Lost

Improvement in Race-Based Disparities in Years of Life ...

Decline in race-based disparities in years of life lost seen in the United States from 1990 to 2014

Drug-Related Endocarditis Cases Up From 2007 to 2015

Drug-Related Endocarditis Cases Up From 2007 to 2015

Increase in endocarditis over nine-year study period mirrored increase in concomitant mixed drug use

is free, fast, and customized just for you!

Already a member?

Sign In Now »